DeCure's autonomous Cancer AI scientist is researching a drug-repurposing hypothesis for central nervous system cancer — screening already-approved drugs against its 38-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleCentral nervous system cancer maps to a 38-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for central nervous system cancer is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
serine/threonine kinase 10 (STK10) — STK10 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet trifluoromethyldrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 6EIM · 1.43 Å · ligand ~{N}-[5-[4-[[2-fluoranyl-5-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-1~{H}-benzimidazol-2-yl]furan-2-carboxamide (B6E). Experimental structure, not a prediction.
What the evidence adds up to
A 2011 commentary on the state of neuro-oncology noted that, despite the discovery of novel therapeutic targets, innovative drug delivery methods, and sophisticated imaging, patient survival had scarcely changed in 30 years. The author stated that the field had accumulated much information but little useful knowledge, and that the nervous system had supplanted the bone marrow as the dose-limiting organ for much of modern cancer therapy. A 2018 review described the accepted influence of the nervous system on cancer growth and metastasis, and summarised preclinical and clinical evidence for repurposing anti-β-adrenergic, anticholinergic, antipsychotic, and antidepressant medications to treat some cancers. The review also discussed physical and chemical denervation as potential treatments. A 2025 chapter on radiotherapy and chemotherapy for central nervous system tumours described the broad range of primary and metastatic CNS neoplasms, the associated morbidity and mortality, and the need for a multidisciplinary approach combining neurosurgery, radiation oncology, medical oncology, and neurology. It focused on treatment-related neurologic complications and their management.
The 2011 commentary explicitly stated that little progress had been made in treating malignant primary brain tumours and that scepticism among neuro-oncologists persisted for good reason. The 2018 review presented the use of nervous-system-targeting medications as a promising addition or alternative strategy, but provided no specific survival or response data from the abstracts themselves. The 2025 chapter introduced principles of radiotherapy and chemotherapy without reporting any new trial results or comparative outcomes.
What is still missing are large, randomised trials that test specific repurposed drugs against standard care in defined CNS tumour subtypes, with overall survival as the primary endpoint. The 2011 commentary highlighted a need for a new paradigm in drug development and clinical selection, but no such paradigm has been delivered in the abstracts provided. Patient stratification by tumour genetics, blood-brain barrier penetration, and nervous-system toxicity remains poorly addressed in the evidence summarised here. Funding for adequately powered trials in primary CNS malignancies, rather than further preclinical reviews, is the clear gap.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Anti-Cancer Drugs · 2018 · 2 citations
The nervous system
AbstractDuring cancer progression, tumor cells interact with the neighboring environment, including neuronal tissue. The important influence of the nervous system on growth and metastasis of cancer is now widely accepted. As such, using medications that traditionally target the nervous system may be an avenue toward treating cancer. The focus of this review is to detail how several classes of medications, traditionally used to treat nervous system disorders, impact cancer. Specifically, we review the preclinical and clinical evidence that support the use of anti-β-adrenergic, anticholinergic, antipsychotic, and antidepressant medications to treat some cancers. In addition, we discuss the use of ablative modalities, such as physical and chemical denervation, to treat cancer or protect against cancer development. Using the medications that target the nervous system to treat cancer is a promising addition to an existing therapy or an alternative treatment strategy. Furthermore, rapidly expanding basic science research in this area will likely yield novel cancer therapies that work by targeting the nervous system.
AbstractAt the recent Society for Neuro-Oncology meeting in Montreal, more than a few clinicians and scientists concluded (as they do every year) that little progress has been made in the treatment of malignant primary brain tumors. Skepticism persists among neuro-oncologists for good reason. Despite the discovery of novel therapeutic targets, innovative methods of drug delivery, and sophisticated imaging modalities, patient survival has scarcely changed in 30 years. Sadly, we have accumulated much information, but little useful knowledge. In addition to a lack of progress in treating primary brain tumors, the threat of nervous system toxicity as a consequence of chemotherapy and cranial irradiation looms ever larger, not just in patients with nervous system cancer, but in all patients with cancer. In fact, a good case can be made that the nervous system has supplanted the bone marrow as the dose-limiting end organ for much of modern-day cancer therapy. Clearly we need a new paradigm for developing drugs in the laboratory and selecting drugs in the clinic.
In this issue of Neurology ®, Gong et al.1 address these …
Oxford University Press eBooks · 2025 · 0 citations
Radiotherapy and Chemotherapy for Central Nervous System Tumors
AbstractAbstract Central nervous system (CNS) tumors represent a broad range of neoplasms that are associated with considerable morbidity and mortality risks. Primary tumors of the CNS include those arising from cells of the brain, spinal cord, and meninges. Systemic malignancies can metastasize to the CNS and affect the brain and spinal cord parenchyma, meninges, and epidural space. Treatment requires a multidisciplinary approach that combines neurosurgery, radiation oncology, medical oncology, and neurology. This chapter introduces principles of radiotherapy and chemotherapy, with a focus on CNS tumors and on potential treatment-related neurologic complications and their management.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
